Comparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection for Diabetic Macular Edema

키워드

참고문헌 (37)

1. William EB, "Diabetic retinopathy. In Duane’s clinical ophthalmology on CD-ROM" (2004), Lippincott Williams & Wilkins
2. Jonas JB, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema", Am J Ophthalmol, 132, pp.425~427 (2001)
3. Audren F, "Intravitreal triamcinolone acetonide for diffuse diabetic macular edema:phase 2 trial comparing 4 mg vs 2 mg", Am J Ophthalmol, 142, pp.794~799 (2006)
4. Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema", Ophthalmology, 109, pp.920~927 (2002)
5. Jonas JB, "Intravitreal triamcinolone acetonide for diabetic retinopathy", Dev Ophthalmol, 39, pp.96~110 (2007)
6. Massin P, "Intravitreal triamcinolone acetonide for diabetic diffuse macular edema:preliminary results of a prospective controlled trial", Ophthalmology, 111, pp.218~224 (2004)
7. Sutter FK, "Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment:three-month efficacy and safety results of a prospective,randomized,double-masked,placebo-controlled clinical trial", Ophthalmology, 111, pp.2044~2049 (2004)
8. Bonini-Filho MA, "Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema:a randomized clinical trial", Invest Ophthalmol Vis Sci, 46, pp.3845~3849 (2005)
9. Karacorlu M, "Intravitreal triamcinolone as a primary therapy in diabetic macular oedema", Eye(Lond), 19, pp.382~386 (2005)
10. Haritoglou C, "Intravitreal bevacizumab(Avastin)therapy for persistent diffuse diabetic macular edema", Retina, 26, pp.999~1005 (2006)
11. Arevalo JF, "Primary intravitreal bevacizumab(Avastin)for diabetic macular edema:results from the Pan-American Collaborative Retina Study Group at 6-month follow-up", Ophthalmology, 114, pp.743~750 (2007)
12. Cunningham ET Jr, "A phase II randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema", Ophthalmology, 112, pp.1747~1757 (2005)
13. Chun DW, "A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema", Ophthalmology, 113, pp.1706~1712 (2006)
14. Jonas JB, "Intravitreal injection of triamcinolone for diffuse diabetic macular edema", Arch Ophthalmol, 121, pp.57~61 (2003)
15. Ciardella AP, "Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates:an optical coherence tomography study", Br J Ophthalmol, 88, pp.1131~1136 (2004)
16. Kim HK, "Laser photocoagulation in diabetic macular edema", J Korean Ophthalmol Soc, 33, pp.759~763 (1992)
17. Paccola L, "Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema(IBEME study)", Br J Ophthalmol, 92, pp.76~80 (2008)
18. 오세범, "당뇨황반부종의 치료에서 유리체강내 트리암시놀론과 베바시주맙 주입술의 효과 비교", 대한안과학회지, 50(8), pp.1190~1196 (2009), 대한안과학회
19. 김훈동, "당뇨황반부종에서 유리체내 베바시주맙 및 후테논낭하 스테로이드 주입술 병합요법의 효과", 대한안과학회지, 50(11), pp.1652~1656 (2009), 대한안과학회
20. Bakri SJ, "Six-month stability of bevacizumab(Avastin)binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing", Retina, 26, pp.519~522 (2006)
21. Ornek K, "Bevacizumab sterility in multiple doses from a single-use vial", Ann Pharmacother, 42, pp.1425~1428 (2008)
22. Chen YH, "Evaluation of the sterility,stability,and efficacy of bevacizumab stored in multiple-dose vials for 6 months", J Ocul Pharmacol Ther, 25, pp.65~69 (2009)
23. Diabetic Retinopathy Clinical Research Network, "A randomized trial comparing intravitreal triamcinolone acetonide and focal", grid photocoagulation for diabetic macular edema, 2008, pp.115, 1447~1449
24. McCuen BW 2nd, "The lack of toxicity of intravitreally administered triamcinolone acetonide", Am J Ophthalmol, 91, pp.785~788 (1981)
25. Moshfeghi DM, "Acute endophthalmitis following intravitreal triamcinolone acetonide injection", Am J Ophthalmol, 136, pp.791~796 (2003)
26. Nelson ML, "Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection", Retina, 23, pp.686~691 (2003)
27. Roth DB, "Noninfectious endophthalmitis associated with intravitreal triamcinolone injection", Arch Ophthalmol, 121, pp.1279~1282 (2003)
28. Audren F, "Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema:6-month results of a prospective controlled trial", Acta Ophthalmol Scand, 84, pp.624~630 (2006)
29. Chan CK, "Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema", Br J Ophthalmol, 90, pp.1137~1141 (2006)
30. Konstantopoulos A, "Ocular morbidity associated with intravitreal triamcinolone acetonide", Eye(Lond), 21, pp.317~320 (2007)
31. Khairallah M, "Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates", Retina, 25, pp.835~839 (2005)
32. Bucher RS, "Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment", Arch Ophthalmol, 123, pp.649~653 (2005)
33. Westfall AC, "Acute endophthalmitis incidence:intravitreal triamcinolone", Arch Ophthalmol, 123, pp.1075~1077 (2005)
34. Wu L, "Twelve-month safety of intravitreal injections of bevacizumab(Avastin):results of the Pan-American Collaborative Retina Study Group(PACORES)", Graefes Arch Clin Exp Ophthalmol, 246, pp.81~87 (2008)
35. Fintak DR, "Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab", Retina, 28, pp.1395~1399 (2008)
36. Mason JO 3rd, "Incidence of acute onset endophthalmitis following intravitreal bevacizumab(Avastin)injection", Retina, 28, pp.564~567 (2008)
37. Diago T, "Infectious endophthalmitis after intravitreal injection of antiangiogenic agents", Retina, 29, pp.601~605 (2009)

관련 논문AI추천